De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

IDEAYA Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van IDEAYA Biosciences is gedaald met een gemiddeld jaarlijks percentage van -28.8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.7%. De inkomsten zijn groeide met een gemiddeld percentage van 28.3% per jaar.

Belangrijke informatie

-28.8%

Groei van de winst

35.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	28.3%
Rendement op eigen vermogen	-16.5%
Nettomarge	-1,285.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

Aug 25

IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M

Aug 15

IDEAYA, Amgen in clinical trial deal for small molecule cancer agent

Jul 27

Ideaya: Next 6 Months Critical For Precision Oncology Biotech

Jun 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

May 16

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Apr 12

Opbrengsten en kosten

Hoe IDEAYA Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:IDYA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	12	-154	34	0
31 Mar 24	16	-129	30	0
31 Dec 23	23	-113	28	0
30 Sep 23	23	-103	27	0
30 Jun 23	45	-74	26	0
31 Mar 23	47	-68	24	0
31 Dec 22	51	-59	24	0
30 Sep 22	50	-53	23	0
30 Jun 22	29	-66	22	0
31 Mar 22	32	-55	21	0
31 Dec 21	28	-50	20	0
30 Sep 21	36	-37	19	0
30 Jun 21	36	-30	17	0
31 Mar 21	27	-31	17	0
31 Dec 20	20	-34	15	0
30 Sep 20	9	-40	14	0
30 Jun 20	0	-46	13	-17
31 Mar 20	0	-44	11	-8
31 Dec 19	0	-42	10	0
30 Sep 19	0	-40	9	8
30 Jun 19	0	-42	7	37
31 Mar 19	0	-38	6	35
31 Dec 18	0	-34	5	0

Kwaliteitswinsten: IDYA is momenteel verliesgevend.

Groeiende winstmarge: IDYA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: IDYA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 28.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van IDYA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: IDYA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: IDYA heeft een negatief Return on Equity ( -16.5% ), omdat het momenteel verliesgevend is.

IDEAYA Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Consensus revenue estimates fall by 32%

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Consensus revenue estimates increase by 10%

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock.

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

Chief Scientific Officer notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

President notifies of intention to sell stock

Consensus revenue estimates fall by 28%

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Price target increased by 12% to US$49.11

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Principal Accounting Officer notifies of intention to sell stock

Price target increased by 8.2% to US$43.70

Co-Founder notifies of intention to sell stock

Price target increased by 7.7% to US$42.10

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 25%

Price target increased by 7.8% to US$35.08

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Legal Officer & Company Secretary notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

Chief Legal Officer & Company Secretary exercised options and sold US$64k worth of stock

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to US$28.11

Co-Founder exercised options to buy US$160k worth of stock.

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Price target increased to US$23.38

Consensus revenue estimates increase by 85%

Price target increased to US$23.38

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data